US Stock Movements: Equifax surges on October 22—rating upgrade, Q3 growth, and credit services
Bitget异动解读2026/10/22 18:31Equifax October 22: Major Price Surge Interpretation
Keywords: Rating Upgrade, Q3 Growth, Credit Services
1. On October 22, Argus Research upgraded Equifax's rating from “Hold” to “Buy,” setting a target price of USD 200. Related analysis points out that the company has shown improved growth, and its new consumer credit scoring model has increased its market share.
2. On October 20, the company announced revenue of USD 1.693 billion for the third quarter of 2026, an approximate 10% year-on-year increase. Adjusted earnings per share were USD 2.26, surpassing the market expectation of USD 2.20. Revenue from diversified markets grew by 8%, and U.S. mortgage income increased by 15%. The company provides data services such as financial information to support business credit decision-making and risk management.
(Disclaimer: This content is generated by AI technology based on public information, for reference only. It does not constitute investment advice.)
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
Google Cloud officially launches Claude model deployment option managed by Anthropic
SpaceX says any potential merger with Tesla still requires further approval
Moderna plunges by as much as 26%, setting a record for the biggest single-day drop! Melanoma vaccine data leaked early, results fall short of expectations
Clinical trial data from phase 3 of the personalized melanoma vaccine jointly developed by Moderna and Merck was unexpectedly leaked ahead of schedule. The data showed a 42% reduction in cancer recurrence risk and a 38% reduction in risk of distant metastasis. These results fell short of market expectations, as an earlier study had shown the combination therapy could reduce recurrence risk by 49% and distant metastasis risk by 59%. Moderna's stock price plunged as much as 26% intraday, later rebounded partially, and ultimately closed down 17.6%.
Crypto prices
More
